Regulations.gov document
Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the…
Notice · FDA-2024-N-5381 · posted Dec 27, 2024
Key facts
| Document ID | FDA-2024-N-5381-0001 |
|---|---|
| Title | Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence |
| Document type | Notice |
| Subtype | Announcement |
| Agency | FDA |
| Docket | FDA-2024-N-5381 |
| Posted | Dec 27, 2024 |
| Federal Register citation | 89 FR 105613 |
| FR document number | 2024-30776 |
| Comment period opens | Dec 27, 2024 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: